Autoimmune liver disease

Diagnosis of ALDs relies on a combination of clinical assessment, liver function tests, histology, imaging, and serological detection of disease-specific autoantibodies.¹ AIH is associated with antibodies against cell nuclei (ANA), smooth muscle (ASMA), soluble liver antigen/liver-pancreas antigen (SLA/LP), liver cytosolic antigen type 1 (LC-1), and anti-liver kidney microsome (anti-LKM1).^2,3 PBC is characterized by ANA and anti-mitochondrial antibodies (AMA),^4,5 while PSC typically exhibits perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA).^6,7 The American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) endorse serological testing as a first-line diagnostic tool for suspected autoimmune liver diseases, recommending indirect immunofluorescence assays (IFA) on a combination of rodent tissues as the gold-standard.^2-5

Euroimmun’s BIOCHIP technology allows the combination of substrates such as rat liver, kidney, and stomach to enhance recognition of autoantibody-specific fluorescent patterns.

Additionally, Euroimmun provides a range of solid-phase assays, including ELISA and EUROLINE immunoblots, covering autoantibodies relevant to AIH, PBC, and PSC. These monospecific assays detect antibodies against targets such as Sp100, gp210, PML, AMA, F-actin, LC-1, LKM-1, and SLA/LP.